[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laboratoire Dermatologique ACM\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100598428","comparison-of-a-cosmetic-serum-and-4-hydroquinone-for-treating-melasma-over-84-days-100598428",false,"NCT07071363","COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS","COMPARATIVE EVALUATION OF THE DERMATOLOGICAL TOLERANCE AND EFFICACY OF A COSMETIC SERUM VERSUS A 4% HYDROQUINONE-BASED PRODUCT IN SUBJECTS WITH MELASMA, AFTER 84 DAYS OF USE - STUDY CONDUCTED UNDER DERMATOLOGICAL SUPERVISION","Inclusion Criteria:\n\nMale or female subjects, primarily female, aged 18 to 65 years at the time of inclusion\n\nFitzpatrick skin phototype II to V\n\nDiagnosed with mild to moderate epidermal or mixed-type facial melasma, confirmed by Wood's lamp examination\n\nmMASI score between 3.5 and 13 at baseline\n\nSubject is in general good health as assessed by the investigator based on medical history and clinical examination\n\nWilling to avoid excessive sun exposure and use only the provided SPF50+ sunscreen during the study\n\nAble to understand the study procedures and provide written informed consent\n\nWilling and able to comply with study procedures and scheduled visits\n\nWomen of childbearing potential must agree to use a reliable method of contraception for at least 3 months prior to and during the entire study duration\n\nExclusion Criteria:\n\nPresence of post-inflammatory hyperpigmentation (PIH), lentigines, or other non-melasma facial pigmentation\n\nUse of topical or systemic depigmenting treatments, retinoids, corticosteroids, or hormonal treatments within 4 weeks prior to baseline\n\nKnown allergy or hypersensitivity to any component of the investigational or comparator products\n\nExcessive sun exposure or use of tanning beds within 2 weeks before baseline or planned during the study\n\nActive skin diseases (e.g., atopic dermatitis, psoriasis) or damaged skin in the test area\n\nPregnant or breastfeeding women, or those planning to become pregnant during the study\n\nParticipation in another clinical trial within 4 weeks prior to the study or planned participation in another trial during the study\n\nHistory of malignancy in the past 10 years (except treated basal cell carcinoma)\n\nUncontrolled systemic illness (e.g., diabetes, cardiovascular, hepatic, renal, or pulmonary disease)\n\nAny psychological or cognitive condition that would limit the subject's ability to understand the study procedures\n\nCurrent use of photosensitizing medications\n\nBMI \\> 40 or other conditions that may affect protocol compliance as judged by the investigator","ALL","18 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with mild to moderate epidermal or mixed-type melasma.\n\nThe main questions it aims to answer are:\n\nDoes the cosmetic serum reduce the severity of melasma (measured by mMASI) after 84 days of use?\n\nIs the cosmetic serum better tolerated than 4% hydroquinone under real-use conditions?\n\nResearchers will compare the serum group and the hydroquinone group to determine whether the cosmetic product achieves comparable pigmentation improvement with superior skin tolerability.\n\nParticipants will:\n\nGroup 1: Apply a morning routine (Depiwhite Serum + Depiwhite M SPF50+ cream) Apply an evening routine (Depiwhite Serum + Placebo Cream without Hydroquinone)\n\nGroup 2: Apply a morning routine (Serum Placebo + Depiwhite M SPF50+ cream) Apply an evening routine (Serum Placebo + Depigmenting Cream with hydroquinone 4%)\n\nVisit the clinical site at baseline (Day 0), Day 56, and Day 84 for assessments\n\nComplete standardized photographs, self-assessment questionnaires, and quality-of-life surveys (MELASQoL and ASLQI)\n\nUndergo clinical evaluations by a dermatologist, including mMASI scoring and tolerance assessment",[27,28,29],"Healthy","Melasma (Facial Melasma)","Epidermal Melasma",[31,32,33],"Melasma","Hyperpigmentation Skin","Pigmentation Disorders","RECRUITING","2025-08-15",{"date":37,"type":38},"2025-08-20","ACTUAL",{"date":40,"type":38},"2025-06-23",{"date":42,"type":21},"2025-12-22",{"name":44,"class":45},"Laboratoire Dermatologique ACM","INDUSTRY",""]